Grünenthal Entered into a License Agreement with Shionogi for Resiniferatoxin (RTX) to Treat Pain Associated with Knee Osteoarthritis
Shots:
- Grünenthal to receive ~$525M incl. $75M up front & is eligible to receive $70M in milestones before regulatory approval along with additional sales-based fees
- Shionogi to get exclusive commercialization rights for Resiniferatoxin (RTX) in Japan. Resiniferatoxin (TRPV1 agonist) is currently being studied in the P-III trial for pain associated with osteoarthritis of the knee across sites in the EU, US, Latin America, South Africa & Japan
- If the P-III trial results are positive, Grünenthal plans to advance the RTX for osteoarthritis-related pain in other joints. If RTX is approved, it will be a non-opioid therapy option that provides long-lasting pain relief along with functional improvement of the affected knee joint & will be well tolerated
Ref: PR Newswire | Image: Shionogi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
